Most Read Articles
Jairia Dela Cruz, 2 days ago
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Dr. Jay Zhu, Dr. Lai Fung Li, Prof. Chae-Yong Kim, 27 Nov 2019
The current standard of care for glioblastoma multiforme (GBM), an aggressive primary brain tumour with a rapid disease course, consists of maximum safe surgical resection followed by radiotherapy with concomitant temozolomide (TMZ) chemotherapy and subsequent TMZ maintenance. At the 16th Annual Meeting of the Asian Society of Neuro-Oncology (ASNO) in Taipei, Taiwan, experts reviewed the evidence and shared their clinical experience on the use of tumour treating fields (TTFields), a novel treatment modality for GBM. 
Stephen Padilla, 2 days ago
There appears to be no significant survival difference between first-line immune checkpoint inhibitor (ICI) and carboplatin-based chemotherapy in cisplatin-ineligible metastatic urothelial carcinoma patients, according to a Taiwan study presented at the recent 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).

Antidepressant use after colon cancer diagnosis does not increase risk of recurrence

17 Feb 2019

Though the use of antidepressants after diagnosis is widespread among colon cancer patients, it does not appear to increase the risk of recurrence, reports a new study.

Of the 1,923 adult colon cancer patients (aged 18 years; 52.4 percent male) included in the study, 807 reported any antidepressant use after being diagnosed. The resulting prevalence rate was 42 percent. Only those with stage I–IIIA malignant adenocarcinoma of the colon or of the rectosigmoid junction were eligible for inclusion.

Over a median follow-up of 4.7 years (10,831 person-years), 139 participants had cancer recurrence, yielding a recurrence rate of 12.8 per 1,000 person-years. There was no significant difference in the risk of recurrence between those who did and did not use antidepressants after diagnosis (hazard ratio [HR], 1.14; 95 percent CI, 0.69–1.87).

Analysis according to type of antidepressant used produced similar results. The use of neither selective serotonin reuptake inhibitors (SSRI; HR, 1.22; 0.64–2.30) nor tricyclic antidepressants (TCA; HR, 1.18; 0.68–2.07) significantly increased the likelihood of colon cancer recurrence.

In a secondary analysis, antidepressant use also did not significantly increase the risk of developing a second primary colorectal cancer (HR, 1.32; 0.86–2.02; SSRIs: HR, 1.16; 0.68–1.99; TCA: HR, 1.24; 0.77–2.00).

The findings were robust to various sensitivity analyses, wherein the definition of colorectal cancer was expanded or the sample was restricted to those with at least two antidepressant prescriptions or those without prediagnosis medication use.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 2 days ago
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Dr. Jay Zhu, Dr. Lai Fung Li, Prof. Chae-Yong Kim, 27 Nov 2019
The current standard of care for glioblastoma multiforme (GBM), an aggressive primary brain tumour with a rapid disease course, consists of maximum safe surgical resection followed by radiotherapy with concomitant temozolomide (TMZ) chemotherapy and subsequent TMZ maintenance. At the 16th Annual Meeting of the Asian Society of Neuro-Oncology (ASNO) in Taipei, Taiwan, experts reviewed the evidence and shared their clinical experience on the use of tumour treating fields (TTFields), a novel treatment modality for GBM. 
Stephen Padilla, 2 days ago
There appears to be no significant survival difference between first-line immune checkpoint inhibitor (ICI) and carboplatin-based chemotherapy in cisplatin-ineligible metastatic urothelial carcinoma patients, according to a Taiwan study presented at the recent 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).